Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK And Pfizer Join Forces In New HIV-Focused Venture

This article was originally published in The Pink Sheet Daily

Executive Summary

ViiV Healthcare will market the two companies' combined portfolio of 10 HIV drugs while also taking over a 17-compound R&D operation.
Advertisement

Related Content

In Another Pfizer Fire Sale, VC-Backed Conatus Acquires Idun's Idle Assets
ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III
ViiV Offers Entire HIV/AIDS Portfolio To Generic Firms In Low-Income Countries, No Royalties Attached
Asset Finance Funds Aim for Pharma Cash, Partnerships
R&D Swapping: AstraZeneca Lures Mackay From Pfizer To Head Global R&D
With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate
Biomarkers For Alzheimer's, Parkinson's Disease To Be Developed By Industry Coalition Through First-Of-A-Kind Clinical Data Exchange
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
FDA Expands Selzentry Indication, But Ties Use To Screening With "Highly Sensitive" Assay

Topics

Advertisement
UsernamePublicRestriction

Register

PS068811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel